163 related articles for article (PubMed ID: 15579519)
1. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
Strippoli GF; Craig JC; Manno C; Schena FP
J Am Soc Nephrol; 2004 Dec; 15(12):3154-65. PubMed ID: 15579519
[TBL] [Abstract][Full Text] [Related]
2. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease.
Strippoli GF; Manno C; Schena FP; Craig JC
Cochrane Database Syst Rev; 2003; (1):CD003967. PubMed ID: 12535495
[TBL] [Abstract][Full Text] [Related]
3. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.
Strippoli GF; Navaneethan SD; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD003967. PubMed ID: 17054191
[TBL] [Abstract][Full Text] [Related]
4. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
5. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
6. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
9. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
Covic A; Seica A; Gusbeth-Tatomir P; Goldsmith D
J Nephrol; 2008; 21(4):478-84. PubMed ID: 18651536
[TBL] [Abstract][Full Text] [Related]
10. Evidence for optimal hemoglobin targets in chronic kidney disease.
Navaneethan SD; Bonifati C; Schena FP; Strippoli GF
J Nephrol; 2006; 19(5):640-7. PubMed ID: 17136694
[TBL] [Abstract][Full Text] [Related]
11. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
12. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease?
Paoletti E; Cannella G
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S74-7. PubMed ID: 16565252
[TBL] [Abstract][Full Text] [Related]
13. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
14. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
[TBL] [Abstract][Full Text] [Related]
15. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure.
Parfrey PS
Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):177-81. PubMed ID: 21157336
[TBL] [Abstract][Full Text] [Related]
16. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
Coyne DW
Semin Dial; 2008; 21(3):212-6. PubMed ID: 18363603
[TBL] [Abstract][Full Text] [Related]
17. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
19. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis.
Amaral S; Hwang W; Fivush B; Neu A; Frankenfield D; Furth S
J Am Soc Nephrol; 2006 Oct; 17(10):2878-85. PubMed ID: 16943308
[TBL] [Abstract][Full Text] [Related]
20. [Anemia as a risk factor for CKD and CVD].
Tsuruya K; Hirakata H
Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
